Oprozomib (ONX 0912)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Mechanism of action

From NCI drug dictionary: An orally bioavailable proteasome inhibitor with potential antineoplastic activity. Oprozomib inhibits the activity of the proteasome, thereby blocking the targeted proteolysis normally performed by the proteasome; this may result in an accumulation of unwanted or misfolded proteins. Disruption of various cell signaling pathways may follow, eventually leading to the induction of apoptosis and inhibition of tumor growth.

Preliminary data

Multiple myeloma

  1. Abstract: Ravi Vij, MBBS, MD, Michael Savona, MD, David S. Siegel, MD, PhD, Jonathan L. Kaufman, MD, Ashraf Badros, MD, Irene M. Ghobrial, MD, Agne Paner, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Linda L. Neuman, MD, MBA, Ju RueyJiuan Lee, PhD and Jesus G. Berdeja, MD. Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. ASH 2014 Abstract 34 link to abstract
  2. Abstract: Parameswaran N. Hari, MD, Kenneth H. Shain, MD, PhD, Peter M. Voorhees, MD, Nashat Gabrail, MD, Muneer H. Abidi, MD, Jeffrey Zonder, MD, Ralph V. Boccia, MD, Paul G. Richardson, Linda L. Neuman, MD, MBA, Sandra J. Dixon, MS and Claudia Paba Prada, MD. Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study. ASH 2014 Abstract 3453 link to abstract

Also known as

  • Code name: ONX 0912